

UNITED STATES OF AMERICA
before the
SECURITIES AND EXCHANGE COMMISSION

SECURITIES EXCHANGE ACT OF 1934
Release No. 97698 / June 12, 2023

Admin. Proc. File No. 3-19789

In the Matter of
CNS PHARMACEUTICALS, INC.,
and
JOHN M. CLIMACO

ORDER GRANTING REQUEST TO WITHDRAW PETITION FOR TERMINATION OF
TRADING SUSPENSION AND DISMISSING PROCEEDING

On May 1, 2020, the Commission issued an order pursuant to Section 12(k) of the Securities Exchange Act of 1934 suspending trading in the securities of CNS Pharmaceuticals, Inc. (“CNS”) (CIK No. 0001729427) for the period from 9:30 a.m. EDT on May 4, 2020, through 11:59 p.m. EDT on May 15, 2020.¹ On May 8, 2020, CNS and John M. Climaco, CNS’s Chairman and CEO, filed a petition to terminate the trading suspension pursuant to Rule of Practice 550.² On May 11, 2020, the Commission requested additional written submissions in accordance with Rule of Practice 550(b).³ On May 29, 2020, CNS and Climaco withdrew their petition. On June 12, 2020, the Division of Enforcement requested that the Commission dismiss the petition and terminate the administrative proceeding.

Accordingly, it is ORDERED that CNS and Climaco’s request to withdraw their petition for termination of the trading suspension is granted and this proceeding is dismissed.

By the Commission.

Vanessa A. Countryman
Secretary

¹ *CNS Pharm., Inc.*, Exchange Act Release No. 88802, 2020 WL 2124580 (May 1, 2020).

² 17 C.F.R. § 201.550.

³ 17 C.F.R. § 201.550(b).